Senior Director(s), OD/Talent Management and Communications/HR Project Management: Biopharmaceutical Industry
October 31, 2011: The Stevenson Group has announced the placement of two key HR executives at Aptalis Pharma based in Bridgewater, NJ. Ms. Barbara Keen, PhD will serve as Senior Director for Organizational Development and Talent Management and Mr. James Porter, PhD will serve as Senior Director for Communications and HR Project Management. Ms. Keen, an accomplished HR executive, comes to Aptalis with over 20 years of experience in organizational learning and development, talent management, and human resource management. Prior to joining Aptalis, Barbara headed an independent consulting practice focused on providing support to HR leaders on issues ranging from Organizational Development to Change Management and Learning. Barbara spent most of her career at Bristol-Myers Squibb, where over the span of 16 years she held several HR leadership positions. In her last role at BMS, Barbara served as Executive Director for Global Learning and Development, where as the lead architect of the company's enterprise-wide global function, she focused on leadership development and Lean Sigma initiatives across R&D, manufacturing, and commercial business units. Barbara earned a PhD degree from the State University of New York, University of Buffalo, and a BA in Psychology from the State University of New York, Binghamton University. In her new role at Aptalis, she will be responsible for developing and executing global organizational strategies that result in profitable growth and achievement of the Company's business objectives. Mr. Porter, an experienced communications professional with expertise in cross-functional employee and executive communications, joins Aptalis from Medco Health Solutions, Inc. As Senior Director for Corporate Affairs at Medco, Jim was responsible for driving employee and HR communications as well as providing executive communications support to CEO and management team. Prior to his role at Medco, Jim spent eight years with Sanofi-Aventis, most recently as Director of Executive and Employee Communications, supporting CEO and providing communications leadership and planning in the US. Earlier in his career, Mr. Porter held corporate communications and media relations positions with Cingular Wireless, Vivendi Universal, and Tobacco Merchants' Association. Jim received his PhD and MA degrees in Political Science from Johns Hopkins University, and a BA in History from Rider University. In his new role at Aptalis, Jim will be responsible for creating and implementing global communications strategies that support the Company's vision and objectives.
Vice President and NDA Project Leader: Biopharmaceutical Industry
October 17, 2011: The Stevenson Group has announced the placement of Peter N. Laivins as Vice President, NDA Project Leader at Merrimack Pharmaceuticals. In this highly visible scientific leader role, Mr. Laivins will steer the company's most advanced oncology program, MM-398, as it advances through late stage development, NDA and commercialization. Prior to joining Merrimack Pharmaceuticals, Mr. Laivins headed an independent consulting practice focused on clinical development, mid-stage commercial strategy, launch, and in-line product commercialization for specialty biotech companies in Neuroscience, Oncology, and life-threatening illnesses. Prior to this, he served as Vice President of Strategic Brand Management and Vice President of Strategic Marketing, Alzheimer's Disease at Elan BioPharmaceuticals, where he led the development of commercial strategy to optimize the company's immunotherapy research portfolio. Earlier in his career, Mr. Laivins spent 21 years at Pfizer, Inc. where he held leadership positions of increasing responsibility, culminating in his role as Senior Director and Group Leader within Pfizer's US Oncology Marketing division. Mr. Laivins earned his BS and MBA degrees from McGill University in Montreal, Canada.
Vice President, Medical: Biopharmaceutical Industry
October 3, 2011: The Stevenson Group has announced the placement of Eliel Bayever, MD as Vice President, Medical at Merrimack Pharmaceuticals. Dr. Bayever comes to Merrimack from Johnson & Johnson Ortho Clinical Diagnostics, where as Vice President of Medical Affairs for Cellular Technologies (Veridex/Therakos) he was responsible for the collaboration with franchise clinical and commercial teams to drive growth in the cellular technologies businesses. From 2005 to 2010, he served as Senior Director and Clinical Team Leader for Oncology at Johnson & Johnson Ortho Biotech and their Oncology Research and Development division. In this role, he was in charge of early development, including clinical development for new targeted cancer agents. From 2003 to 2005, he was the Senior Director for Medical Research, Oncology at Wyeth Research, where some of his responsibilities included supporting the mTOR inhibitor development for renal cell carcinoma and breast cancer. Earlier in his career, Dr. Bayever served as Director of Clinical Research at Human Genome Sciences and Associate Director for Anti-Infectives/Biologicals, Medical Research at Bayer Pharmaceuticals. He also held numerous faculty and hospital appointments and acted as the principal investigator on many oncology trials. Dr. Bayever received his Medical degree from the University of Witwatersrand in South Africa. At Merrimack, Dr. Bayever will lead the global clinical strategy for the Company's most advanced program, MM-398, a novel nanoparticle liposome formulation of Irinotecan.
Director, EMEA Sales & Marketing Effectiveness Analytics: Medical Devices Industry
July 20, 2011: The Stevenson Group has announced the placement of Antonio Pregueiro, PhD as Director of EMEA, Sales and Marketing, Effectiveness Analytics at Bausch & Lomb in Zug, Switzerland. Dr. Pregueiro's main responsibility will be to work with country leadership (Europe, Middle East & Africa) to provide key analytical insight to guide informed business decisions and execute against business needs in the areas of market research, business information, analytics, and promotional effectiveness. Prior to joining Bausch & Lomb, Antonio served as Senior Manager of Business Planning and Analytics at Amgen Inc. In this role, he developed product strategies and performed analyses in support of new product launch and company strategy. Prior to his position at Amgen, Dr. Pregueiro served as Consultant at SDG Life Sciences/ IMS Health, where he provided life sciences clients with knowledge on prioritizing and optimizing their portfolio. Antonio began his career in 2004 as Senior Analyst with Trinity Partners and their Business Analytics Pharma Solutions group, where he developed innovative approaches to support and optimize business analytics. He received his BS in Biochemistry and Genetics from University of Sheffield in UK, and a PhD in Genetics, Molecular and Cell Biology from Dartmouth College in Hanover, NH.
Vice President of Information Technology: Specialty Pharma
July 18, 2011: The Stevenson Group has announced the placement of Shauna Tholen as Vice President of Information Technology at Ikaria Inc., a fully integrated bio-therapeutics company focused on development and commercialization of pharmaceuticals and drug-device combinations in critical care. In her new role, Ms. Tholen will collaborate with Ikaria's senior management team to develop a technology vision for the company. Ms Tholen is a seasoned technology executive with over 30 years of experience leading and executing strategy across Enterprise Applications, Infrastructure, and Architecture within several mid-size and big pharma organizations. Most recently, Ms. Tholen served as Chief Information Officer at Nycomed US, a specialty pharmaceutical company with focus in dermatology, where she developed and implemented strategic technology vision, technical standards, policies and procedures, and established goals and objectives that supported overall business goals. From 2005 to 2008, Shauna served as Vice President and Chief Information Officer at OSI Pharmaceuticals, where she was in charge of technology strategy and delivery for the company. Earlier in her career, Shauna held key executive positions with Amersham Health, Pfizer, and Novartis where she developed, defined, and implemented numerous technology plans and "best in class" processes to improve and optimize business objectives. Ms. Tholen received her Bachelor's degree from the University of Denver in Denver, Colorado.
Senior Director, External R&D Innovation: Pharmaceutical Industry
July 18, 2011: The Stevenson Group has recruited Gene Liau, PhD as Head of Orphan and Genetic Diseases Research Unit in the External R&D Innovation organization at Pfizer, Inc. Dr. Liau's main responsibility will be to define and implement the strategy for the ERDI function supporting Pfizer's product pipeline in the Orphan and Genetic Diseases area. Dr. Liau comes to Pfizer with over 13 years of pharmaceutical drug discovery experience and broad scientific knowledge in gene regulation, cardiovascular, rare diseases, genomics, and cancer. Most recently, Dr. Liau served as Director of Discovery Research at Shire HGT, a specialty biopharmaceutical company specializing in discovery and delivery of medicines for rare genetic diseases. In this role, he defined the expansion strategy and evaluated external collaboration opportunities with academic institutions and biotech companies. From 2002 to 2010, Dr. Liau held several positions of increasing responsibility with Novartis Institutes for BioMedical Research (NIBR). In his last role as Senior Investigator at NIBR, Dr. Liau was responsible for championing cardiovascular programs and evaluating external cardiovascular metabolic opportunities. Dr. Liau began his scientific career in 1982 as Postdoctoral Fellow at the National Cancer Institute in Bethesda, MD. Later on, he held key scientific roles with the American Red Cross, George Washington University, and Genetic Therapy, Inc. He has authored and published numerous articles on gene expression and regulation. Dr. Liau received his PhD in Biochemistry from Vanderbilt University in Nashville, TN.
Medical Director, MM-121: Biopharmaceutical Industry
July 5, 2011: The Stevenson Group has announced the placement of Akos G. Czibere, MD/PhD as Medical Director, MM-121 at Merrimack Pharmaceuticals. In his new role, Dr. Czibere will support the development of Merrimack's flagship oncology program MM-121. MM-121 is a fully human monoclonal antibody that targets ErbB3. In collaboration with Sanofi-Aventis, Merrimack is testing MM-121 in combination with both chemotherapies and other targeted agents across a wide spectrum of solid tumors, including lung, breast and ovarian cancers. Dr. Czibere comes to Merrimack with nine years of molecular research experience and four years of clinical experience in hematology and oncology. Prior to joining Merrimack, Dr. Czibere was a Postdoctoral Research Fellow at Harvard University. Prior to this, he served as a Clinical Trial Investigator, Research Scientist, and a Resident at the University Hospital of Düsseldorf in Germany. During that time, he was in charge of designing molecular biological experiments, writing study protocols, generating and evaluating clinical trial data, and clinical care of patients with hematological malignancies and lung cancer. Dr. Czibere earned his PhD and MD degrees from Heinrich-Heine University and Medical School in Düsseldorf, Germany.
Senior Vice President of Operations: Life Sciences Technology
June 6, 2011: The Stevenson Group has recruited Mr. John A. Mosier as Senior Vice President of Operations at iCyt Mission Technology Inc., a subsidiary of Sony Corporation of America. In his new role, Mr. Mosier will be responsible for day-to-day management and operations of all product manufacture, service, technical support, IT, and global product distribution activities. iCyt is a rapidly growing company that designs, manufactures, and delivers flow cytometry instrument products to different markets around the world. Mr. Mosier comes to iCyt with over 18 years of manufacturing, purchasing, and supply chain operations management experience within global organizations. Prior to joining iCyt, Mr. Mosier served as Director of World Wide Manufacturing Operations at FEI Company, a global leader in electron and ion imaging technologies. In that role, he was charged with overseeing capital equipment manufacturing operations and associated supply chain processes supporting new systems sales revenue stream. From 2002 to 2004, Mr. Mosier served as Director of Global Supply Chain and Logistics at Novellus Systems, Inc., a global supplier of semiconductor equipment used to manufacture nano-electronics. At Novellus, John was in charge of service spares supply chain management operations across US, Europe, and Asia. Prior to Novellus, he was a Managing Director for Supply Chain Engineering Services at i2 Technologies, where he led a worldwide engineering services organization. Earlier in his career, John held key positions within the Supply Chain Consulting Practice at Pricewaterhouse Coopers and Ernst & Young. Mr. Mosier received his MBA in Operations Management from Texas A&M University and a Master's degree in International Management from Johannes-Kepler University in Linz, Austria.
Chief Executive Officer: Healthcare Solutions
May 28, 2011: The Stevenson Group is pleased to announce the placement of David Heimbrook, PhD as Chief Executive Officer at SAIC-Frederick, Inc. in Frederick, MD. SAIC-Frederick is a wholly-owned subsidiary of Science Applications International Corporation (SAIC) and operates exclusively under a single, long-term contract to the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. Dr. Heimbrook will replace Dr. Larry Arthur who will be stepping down from his duties as a CEO but will continue to serve as SAIC-Frederick's Chief Scientist. Dr. Heimbrook, an exceptional cancer scientist, comes to SAIC-Frederick with more than 20 years of oncology research and organizational management. Prior to joining SAIC-Frederick, Dr. Heimbrook served as Global Head of Discovery for the Oncology Discovery and Translational Area at Hoffmann-La Roche, Inc. In this role, he was responsible for leading oncology research at all Roche Oncology research sites within Pharma Research and Early Development, developing and implementing the Oncology research strategy for the Company, and transitioning molecules through clinical proof-of-concept to the lifecycle portfolio for pivotal registration studies. Dr. Heimbrook first joined Roche in 2003 as Vice President of Discovery Oncology for the Nutley site and Global Therapeutic Area Head for Oncology across multiple sites. He began his industry career as Postdoctoral Scientist with Smith Kline French Laboratories, and as a Bench Scientist with Merck Research Laboratories. Dr. Heimbrook's career with Merck progressed over a 17 year period, culminating in his appointment as Head of the Department of Cancer Research. At SAIC-Frederick, Dr. Heimbrook will be responsible for all Operations and Technical Support contract activities as well as leading scientific, research, and administrative operations. As the new CEO, he will work closely with the National Cancer Institute (NCI) to ensure the achievement of the NCI's plans and objectives.
Operations and Site Engineering Leadership: Life Sciences
April 15, 2011: The Stevenson Group has announced the placement of three key manufacturing operations leaders at EMD Millipore's facility in Jaffrey, NH. Mr. Joshua Reinhart and Mr. David Poggi will serve as Operations Managers, while Mr. Stacy Caron will serve as a Site Engineering Manager. Josh Reinhart and David Poggi will be responsible for day-to-day and strategic operations of filtration device centers at the Jaffrey plant, while Stacy Caron will be in charge of all aspects of plant engineering within that site. The Stevenson Group and Millipore have partnered since 2008 to help the Company expand their bioprocess manufacturing operations within the US and Mexico. Millipore has been a trusted partner to the biopharmaceutical industry for more than 50 years. The company is best known for manufacturing filters and membranes with micrometer-sized pores, used for everything from basic life sciences research to biologic drug manufacturing. In 2010, Millipore was acquired by a pharmaceutical giant Merck KGaA. Together, Millipore and Merck known as EMD Millipore will have a significant presence in high-growth bioresearch and bio-production segments with an enhanced geographic presence. The recent placements will help the company create an even more powerful innovation platform tailored more closely to the needs of customers. Mr. Reinhart comes to EMD Millipore with eight years of manufacturing operations experience within vaccine, fine chemical, and protein biologics production. Most recently, he served as a Deputy Director of Manufacturing at Sanofi-Pasteur in Canton, MA. Prior to that, he was a Process Technology Engineer at Biopure Corporation. Mr. Reinhart has a Masters degree in Biotechnology from Northeastern University and a BS degree in Chemical Engineering from The Pennsylvania State University. Mr. Poggi joins EMD Millipore with 10 years of experience leading high volume automated manufacturing operations. Prior to his current role, Mr. Poggi spent eight years with Smiths Medical, Inc., first as a Lean Project Manager for Supply Chain/ Materials and most recently as a Manufacturing Manager, where he led continuous improvement activities for seven Medical Device product lines. Mr. Poggi received his Bachelors degree in Finance and Operations Management from the University of Massachusetts. Mr. Caron is an experienced engineering manager executing highly automated processes in medical device manufacturing. Prior to joining EMD Millipore, Mr. Caron was the Engineering Manager with Covidien supporting their Anesthesia Monitoring Devices operations. Previously, he spent about two years with Karl Storz Endovision/ Medical Endoscopy division as a Manufacturing Engineer. Mr. Caron is pursuing an MBA degree from the University of Massachusetts/ Isenberg School of Management and holds a BS degree in Mechanical Engineering from Lehigh University.
Senior Director(s), External R&D Innovation: Pharmaceutical Industry
December 15, 2010: The Stevenson Group has announced the placement of two Senior Directors in the External R&D Innovation group at Pfizer, Inc. Dr. Karim Dabbagh, PhD will be the Head of Inflammation and Immunology Research Unit and Dr. Richard Pittner, PhD, the Head of CV, Metabolics Research Unit, both in the External R&D Innovation (ERDI) organization. Their main responsibility will be to define and implement the strategy for the ERDI function supporting Pfizer’s product pipeline for the therapeutic area of Inflammation and Metabolism respectively. Dr. Dabbagh comes to Pfizer with over 14 years of experience in the fields of respiratory, autoimmune, and inflammatory diseases as well as experience in the pharmaceutical drug development. Prior to joining Pfizer, Dr. Dabbagh was with Modus BioMedicine, Inc., a start-up biotech company he founded to develop novel antibodies for the treatment of transplantation and autoimmune diseases. Karim spent most of his career with Hoffman-La Roche and Roche Palo Alto as a Consultant and Head of Inflammation Discovery Research. Dr. Dabbagh earned his PhD degree in Biochemistry from the University College London. Dr. Pittner, an accomplished R&D executive with 18 years of biotechnology experience and expertise in diabetes/obesity, joins Pfizer from Trinity BioSystems, where as Vice President of Molecular Biology and Protein Engineering, he developed a strategic and operational plan for the evaluation of a unique oral delivery technology. Dr. Pittner spent most of his career with Amylin Pharmaceuticals, where in his last two roles there as Sr. Director of Discovery Biology and Director of Cell and Molecular Biology, he rebuilt lost research capabilities for early-stage exploratory research initiatives. Dr. Pittner received his PhD degree from the University of Nottingham, England.
Head of Pricing and Business Operations: Medical Devices Industry
November 15, 2010: The Stevenson Group has recruited Christopher Maffie as Head of Pricing and Business Operations at GE Healthcare/ Medical Diagnostics division in Princeton, NJ. Mr. Maffie comes to GE with over 18 years of experience in the pharmaceutical, medical device, diagnostic and disease management industry. Prior to joining GE, Mr. Maffie served as a Director of Pricing for North America at Johnson & Johnson. In this role, he was responsible for leading the development and implementation of net pricing strategy for key pharmaceutical brands within J&J across customer channels. His career with J&J spans over 12 years and within different subsidiaries including Symcare, Inc. and LifeScan, Inc. From 1998 to 2004, Mr. Maffie held leadership positions of increasing responsibility within Contracts and Managed Care at Johnson & Johnson Health Care Systems. Prior to 1998, he worked at Schering-Plough Corporation. In his current role, Mr. Maffie will lead all commercial and government operations as pertaining to GE Healthcare/ Medical Diagnostics in the US, Canada, and Latin America. He will drive sales operations processes as well as develop and implement pricing strategies. Mr. Maffie received his MBA and BA degree in Economics from Rutgers University in New Jersey.
Senior Medical Director, Oncology: Biotech Industry
November 1, 2010: The Stevenson Group has announced the placement Samuel V. Agresta, MD as Senior Oncology Medical Director at Merrimack Pharmaceuticals based in Cambridge, MA. In this clinical leadership role, Dr. Agresta will advance the company’s robust pipeline of system biology driven oncology programs, most notably, the company’s bi-specific antibody currently being studied in a variety of solid tumors. Prior to joining Merrimack Pharmaceuticals, Dr. Agresta served as a Medical Director at Genentech, Inc. where he was the clinical trial lead overseeing Phase I-III clinical trial development for T-DM1, an antibody-drug-conjugate with indication for HER2 Positive Metastatic Breast Cancer. His overall clinical development experience includes phase I through phase III international translational trial development, globalization of development plans, and managing global KOL relationships. Prior to his industry position with Genentech, Dr. Agresta was the Assistant Professor at the University of South Florida/ H. Lee Moffitt Cancer Center and from 2002 to 2003, he served as Clinical Instructor at Tulane University Health Science Center. Dr. Agresta completed his post-graduate training in Internal Medicine, Hematology and Oncology at Tulane University Health Science Center and H. Lee Moffitt Cancer Center. He has published numerous articles on sarcomas and breast cancer and he is a member of several honor societies. Dr. Agresta earned an M.D. degree from Tulane University Medical School in New Orleans, and an M.S. degree in Clinical Investigation from the University of South Florida.
Vice President & General Manager: Generics and Specialty Pharmaceuticals Industry
November 1, 2010: The Stevenson Group has announced the placement of Vincent F. Mancinelli as Vice President/General Manager at Rhodes Pharmaceuticals in Coventry, RI. Mr. Mancinelli comes to Rhodes with over 22 years of pharmaceutical and technical operations experience. Prior to joining Rhodes Pharmaceuticals, Mr. Mancinelli served as the Head of North American Technical Operations and General Manager for Mylan, Inc., overseeing all technical operations of a $2.1 billion combined business located in the United States, Puerto Rico and Canada. Previously, Mr. Mancinelli was the Executive Vice President/General Manager and a Vice President of Quality and Regulatory Affairs at UDL Laboratories, Inc., a division of Mylan, Inc. and a premier supplier of unit dose multi-source pharmaceuticals to the institutional and long-term care marketplace. In his new leadership role at Rhodes Pharmaceuticals, Mr. Mancinelli is charged with developing a portfolio of generic and specialty pharmaceutical products while leading strategic activities across commercial, product development, intellectual property, technical operations, financial planning and regulatory affairs. Mr. Mancinelli earned a BA degree in Biology from West Virginia University in Morgantown, WV.
Senior Customer Segment Manager(s), Market Strategies: Biopharmaceutical Industry
August 31, 2010: The Stevenson Group has announced the placement of Yoni Falkson and Pamela Cousin as Senior Customer Segment Manager(s), Market Strategies at Purdue Pharma L.P. in Stamford, CT. In this new role, Mr. Falkson and Ms. Cousin will be charged with advancing the development and implementation of market segment/ customer-focused plans and objectives related to assigned customer segments and accounts. Mr. Falkson comes to Purdue Pharma from Bridgehead International where as the project and client Consulting Lead he was responsible for global market assessment of future payer landscape in several key therapeutic areas. Prior to Bridgehead International, Yoni was a Consultant with IMS Consulting within their Pharmaceutical Pricing and Market Access group. While at IMS, he managed day to day client project delivery including evaluation of US and global payer reimbursement landscape, emerging markets, and pricing strategies. Yoni has a Bachelors' degree in Psychology and Economics from Cornell University. Ms. Cousin comes to Purdue from Eisai Inc., where as Manager of Contracts and Rebates she led financial forecasting and budgeting for Eisai's US product lines including Managed Markets. Prior to her role as a Manager, Pamela was a Senior Financial Analyst for Eisai's CNS Franchise, providing financial analysis for Aricept, Eisai's CNS flagship product. Earlier in her career, Ms. Cousin worked as a Senior Corporate Accountant for IBM Corporation and a Senior Financial Analyst for Polaroid Corporation. She received her MBA degree in Management and BA degree in Accounting from Bentley University in Waltham, MA.
Senior Director, Preclinical Operations: Biopharmaceutical Industry
June 15, 2010: The Stevenson Group has announced the placement of Donna M. Grant, PhD as Senior Director, Preclinical Operations at Regeneron Pharmaceuticals in Tarrytown, NY. Dr. Grant is an accomplished preclinical scientist with a broad spectrum of pharmaceutical and basic research experience in pharmacokinetics/ADME, toxicology, regulatory submissions and project management. Most recently, she served as a Director of Preclinical Development at Optherion, Inc., where she helped define and implement a toxicology and pharmacokinetics strategy for recombinant human protein therapeutics. Previously, Dr. Grant spent 6 years at Pfizer, Inc. where she held leadership positions of increasing responsibility within Pharmacokinetics, Dynamics and Metabolism (PDM). Earlier in her career, she worked as a Scientist for Biogen Inc., and Purdue Pharma, L.P. As the Senior Director, Preclinical Operations leader at Regeneron Pharmaceuticals, Dr. Grant will manage preclinical development operations across all company programs and establish a sustainable project and program management infrastructure for the department, accountable for timelines, budgeting and resource allocation. She received her PhD degree in Toxicology from North Carolina State University in Raleigh, NC and a MS degree in Biology from Indiana University of Pennsylvania in Indiana, PA.
Executive Director, Clinical Development Laboratory, Early Development: Pharmaceutical Industry
June 7, 2010: The Stevenson Group has announced the placement of Russell Weiner, PhD as Executive Director, Clinical Development Laboratory within the Early Development Group at Merck & Co, Inc. in Rahway, NJ. Dr. Weiner comes to Merck from Bristol-Myers Squibb, where he spent 17 years of his professional career moving progressively up through the scientific ranks. In his last role at BMS, Dr. Weiner served as Group Director of Biomarker and Bioanalytical Sciences, where he was responsible for leading and overseeing the development, validation, and implementation of quantitative immunochemistry and biomarker assays in support of non-clinical and clinical studies. From 2005 to 2007, Dr. Weiner served as Director of Clinical Biomarker Development and was in charge of Clinical Biomarker Development team and Pharmacology Operations, which involved all aspects of pre- and post-study clinical trial logistics. From 2002 to 2006, Dr. Weiner was the Director of Clinical Discovery at BMS Pharmaceutical Research Institute, where he led a team of Medical Directors, Clinical Scientists and Pharmacokinetisists responsible for transitioning pharmaceutical compounds from discovery to exploratory clinical development. In this role he also developed and implemented early clinical development strategies for Immunology and Inflammation pharmaceuticals. A true hybrid of basic science, clinical and regulated GCP, GLP, and GMP environments, Russ is an active member of the American Association of Pharmaceutical Scientists committee, where he currently serves as Chair of the Program Coordination committee. He has co-authored and published numerous white papers on biomarkers and is considered a subject matter expert in the area of Bioanalytics. Russ has received his PhD in Biochemistry from Albany Medical College in Albany, NY. As Executive Director at Merck, Dr. Weiner will be responsible for the expansion of the existing CDL platform to support a broader array of innovative fit for purpose assays and in-vitro diagnostics.
Director, Project Management: Healthcare Solutions
May 24, 2010: The Stevenson Group has recruited Kenneth Low, PhD as Director, Project Management in the Applied and Developmental Directorate, SAIC-Frederick, Inc. at the NCI-Frederick in Rockville, MD. The Applied and Developmental Directorate within SAIC-Frederick comprises of the Clinical Services Program and the Developmental Therapeutics Program Support Group, both of which support the clinical trials and drug development efforts at NCI and NIAID. Dr. Low comes to SAIC with diverse project and program management experience establishing R&D groups and leading innovative studies in preclinical and clinical product development for molecular/cell biology applications. Prior to joining SAIC, Ken served as Senior Director, Development Services at Celsis/In Vitro Technologies, where he managed a team of biologists, analytical chemists, scientific writers, and study directors performing contract research services in ADME-Toxicology studies for pharmaceutical and biotechnology clients entering pre-clinical and clinical trials. From 2004 to 2008, Dr. Low served as Director/Site Head of Cell Culture Research and Strategic Innovation and Portfolio Management at Gibco/Invitrogen Corporation. In this role, he provided portfolio management leadership for the Cell Culture Systems Division and its business segments in Bio-Production, Cell Culture Research, Stem Cells Research, Sera, and Process Development Direct Services. Earlier in his career, Ken worked as a Group Leader/Head for Target Validation, Bioanalytics, Biomarkers and Preclinical Development at Curagen Corporation, where he consolidated and managed bioanalytical and biomarker identification efforts in preclinical development and animal studies. Dr. Low started his professional and academic career as a Research Fellow for the Department of Neurology at Harvard Medical School. At SAIC-Frederick, he will have the responsibility for developing and managing the direction, planning, and execution of a Project Management Office (PMO) that supports the National Cancer Institute’s Experimental Therapeutics program (NExT).
Medical Directors: Biotech Industry
April 5, 2010: The Stevenson Group has announced the placement of two Medical Directors at Reata Pharmaceuticals, headquartered in Irving, TX. Dr. Anil Kumar and Dr. Matthew Frankel will be responsible for providing clinical development expertise, management, and leadership for late stage development activities. Reata is a biotechnology company developing a portfolio of antioxidant inflammation modulators (AIMs) for a variety of inflammation-related diseases. Dr. Kumar most recently served as Professor of Surgery at Drexel University College of Medicine. During his 26 years in academic medicine, Dr. Kumar published more than 80 peer-reviewed articles and was an invited expert speaker at over 100 national and international meetings focused on kidney transplantation and immuno-suppression. Dr. Kumar is a Fellow of the Royal College of Surgeons and received his MD degree from University of Mysore in India. Dr. Frankel most recently served as Medical Director of Clinical Development at FibroGen, Inc. where he was the clinical lead overseeing development of a novel molecule for treatment of anemia in Chronic Kidney Disease. His previous positions were with PDL BioPharma Inc. as Medical Director of Clinical Development, and Schering-Plough Corporation as Senior Oncology Regional Medical Science Liaison. Dr. Frankel received his MBA from Northwestern University and his MD degree from UCLA.
Senior Director, Corporate Technical Science: Biotech Industry
April 5, 2010: The Stevenson Group has announced the placement of Ranjit Deshmukh, PhD as Senior Director, Corporate Technical Science at MedImmune in Gaithersburg, MD. Most recently Dr. Deshmukh served as Senior Director of Technical Development and Transfer at Wyeth Pharmaceuticals. He was accountable for implementation of best practices and continuous improvement across the company. Prior to his most recent role, Dr. Deshmukh held positions of increasing responsibility within the Technical Development and Transfer area at Wyeth. He has over 15 years of experience in manufacturing science, commercial manufacturing, technology transfer, and late stage process development. In his new role as Senior Director, Corporate Technical Science at MedImmune, Dr. Deshmukh will provide high-level scientific as well as technical expertise to the Operations function. He will help to ensure the Quality of work within MedImmune by directing policies and partnering with the manufacturing sites across the company. Dr. Deshmukh received his PhD in Chemical Engineering from the University of Arizona in Tucson.
Senior Director, Regulatory Affairs: Biotech Industry
March 15, 2010: The Stevenson Group has announced the placement of Michael Slater as Head of Regulatory Affairs & Quality at Merrimack Pharmaceuticals based in Cambridge, MA. Mr. Slater comes to Merrimack with more than 20 years of experience in preclinical and clinical regulatory strategy development and quality systems. He’s charged with enhancing and establishing the company’s regulatory and quality infrastructure, serving as a key interface with global regulatory agencies, and driving regulatory strategy for a robust pipeline of early and mid-stage oncology programs. Prior to joining Merrimack Pharmaceuticals, Mr. Slater served as a senior regulatory consultant for Millennium Pharmaceuticals, responsible for developing regulatory and post-marketing life cycle strategy for oncology therapeutics, including VELCADE. Previously, he was the Senior Vice President of Regulatory Affairs and Operations for Acusphere, Inc. serving as the primary interface with the FDA and leading the IND/NDA review and submission process. Earlier in his career, Mr. Slater spent 10 years at Biogen as the Vice President of Regulatory Affairs, responsible for corporate global regulatory strategies across multiple products and therapeutic areas. Mr. Slater earned an M.I.Inf.Sc. and BS degree from the University of Leeds, UK.
Senior Vice President, Civilian Health Operations: Healthcare Solutions
January 11, 2010: The Stevenson Group has announced the placement of Steven Galson, MD, MPH as Senior Vice President, Civilian Health Operations at SAIC Health Solutions Business Unit, headquartered in McLean, VA. Most recently, Dr. Galson served as Acting Surgeon General of the United States. Dr. Galson also served as the Acting Assistant Secretary of Health, and the Director of the Food and Drug Administration’s Center for Drug Evaluation and Research. Galson also held executive positions in the U.S. Environmental Protection Agency, U.S. Department of Energy, and the Centers for Disease Control and Prevention's National Institute for Occupational Safety and Health. In his new role, Galson will lead SAIC's civilian health team, manage the operation's long-term growth strategy, and help develop new solutions to meet the evolving business needs of SAIC's civilian, public health, and life sciences customers. Galson will report to Anthony Hess, Ph.D., SAIC senior vice president and business unit general manager. Galson is a graduate of the State University of New York at Stony Brook where he earned a Bachelor of Science degree in biochemistry. He later earned a Doctor of Medicine degree from the Mt. Sinai School of Medicine, and a Master of Public Health degree from the Harvard School of Public Health. A retired rear admiral from the U.S. Public Health Service Commissioned Corps, Galson is also board certified in general preventive medicine, public health, and occupational medicine.
Vice President, Sales and Marketing: Generics & Specialty Pharma Industry
September 1, 2009: The Stevenson Group has announced the placement of Robert Thebeau as Vice President, Sales and Marketing at Rhodes Pharmaceuticals in Coventry, Rhode Island. Mr. Thebeau comes to Rhodes with over 20 years of sales, marketing, and management of generic and branded products experience. Mr. Thebeau possesses deep experience in the retail, wholesale, distributor, acute care, long term, managed care, government, and GPO sectors. Most recently, he served as the Vice President of National Accounts and Institutional Products at Dava Pharmaceuticals where he developed and implemented successful sales and marketing strategies that maximized sales and profits of Dava’s generic and branded products. While at Dava, Bob was instrumental in establishing and bringing to market a newly formed institutional product line for their IVY Therapeutics division. Prior to Dava Pharmaceuticals, Mr. Thebeau served as principal partner at CuraMedica, LLC, a start-up generic pharmaceutical consultant services company he co-founded in 2000. During his years at CuraMedica, Bob built and maintained executive level relationships with major wholesalers such as Cardinal and McKesson, and developed Rx product lines and pricing strategies. From 1993 to 2000, Bob held several positions at Schein/Marsam Pharmaceuticals and in his last role as Director of Sales he oversaw the company’s brand and generic sales divisions and played an integral role in forging results-driven cooperation between contracts and sales departments. At Rhodes, Mr. Thebeau will develop and lead commercial opportunities inclusive of delivering and executing marketing and sales strategies and launching new generic products while ensuring competitive penetration into the appropriate distribution channels and networks.
Division Manager, BioProcess Business - Mexico: Life Sciences Technology Industry
August 24, 2009: The Stevenson Group has announced the placement of Alberto Suarez for the position of Division Manager, BioProcess - Mexico at Millipore Corporation. Mr. Suarez, who possesses expertise in process chromatography and filtration systems, comes to Millipore from GE Healthcare Life Sciences based in Mexico City. In his last role as Regional Sales Manager for GE Healthcare Life Sciences, Mr. Suarez leveraged deep experience in the industrial customer segment and was responsible for the division achieving year over year, annual revenue goals. Prior to joining GE Healthcare, Alberto served as Regional Sales Manager for the Caribbean region at Amersham Biosciences AB, which eventually was acquired by GE Healthcare. For seven years prior to the acquisition, Mr. Suarez led the solution sales teams across Cuba, Jamaica, Trinidad and Tobago, Costa Rica, Ecuador and Panama where he consistently received global recognition for his commercial success. Earlier in his career, Alberto served as Head of Biotechnology Division at Immunolab SA, a distributor for Pharmacia and Beckman products. Throughout his entire professional career, Alberto has built businesses around biosciences/laboratory and bioprocess product lines and in his role of Division Manager, BioProcess at Millipore, Mr. Suarez is charged will leading the commercial activities for the company’s emerging bioprocess business and reinforcing their strong positioning in the local region.
Global Director, Scientific Affairs, Respiratory: Pharmaceutical Industry
August 15, 2009: The Stevenson Group has announced the placement of James E. Fish, MD as Global Director, Scientific Affairs - Respiratory for Merck & Company. Dr. Fish has an extensive experience in clinical and translational research related to asthma and chronic obstructive lung disease. He currently holds an appointment as Adjunct Professor of Medicine at Jefferson Medical College in Philadelphia. Prior to joining Merck, Dr. Fish was a Senior Medical Director at Genentech, Inc. where he led the post-marketing activities related to Xolair. During his tenure in the pharmaceutical industry, he has led the strategic planning team for the respiratory disease area at Aventis and participated in the submission of an IND and an NDA for new respiratory products. From 1993 to 2002, Dr. Fish served as a Principal Investigator of the Jefferson Asthma Clinical Research Network Center, one of six Asthma Clinical Research Network Centers designated by the National Heart, Lung, and Blood Institute. His research has focused on the pathogenesis and treatment of asthma and other reactive airways syndromes and COPD. He has published over 160 articles and book chapters and has been cited among the "Best Doctors in America" by several sources including the Naifeh & Smith Survey, Town & Country Magazine, and American Health Magazine. At Merck, he will hold primary responsibility for Scientific Leadership within the Respiratory disease area.
Director, Project Management: Healthcare Solutions
August 7, 2009: The Stevenson Group has recruited Eric Morfin as Director, Project Management in the Applied and Developmental Directorate, SAIC-Frederick, Inc. at the NCI-Frederick in Rockville, MD. The Applied and Developmental Directorate within SAIC-Frederick comprises of the Clinical Services Program and the Developmental Therapeutics Program Support Group, both of which support the clinical trials and drug development efforts at NCI and NIAID. Mr. Morfin joins SAIC with more than 20 years of project leadership experience in the pharmaceutical, biotech, and medical devices industry creating and managing project office functions for global Phase I-IV trials. He comes to SAIC from Amylin Pharmaceuticals, where as Executive Director of Project Management and Process Development he led a group of 45 project managers in all aspects of developing and executing the company programs. Prior to his position at Amylin, Eric worked as Senior Group Director for a clinical research organization, Quintiles where as the Biotech Group’s leader he was responsible for establishing new partnerships and implementing the overall business development strategy. From 2003 to 2007, Eric served as Director for the Project Management Office at Novartis’ Vaccines and Diagnostics division. While at Novartis, he led the development and implementation of a unique stage gate product development process related to the discovery, development, manufacturing, and marketing of infectious disease and vaccine products. Earlier in his career, Eric worked as a PMO Consultant for the industry and government clients where he led and controlled numerous portfolio and implementation projects. Mr. Morfin is a Founder and Chair of a non-profit organization called BioPharmaPM.org dedicated to the advancement of PM Best Practices in the pharmaceutical industry and a member of several societies and associations focused on best project management practices and training. At SAIC-Frederick, he will have the responsibility for developing and managing the direction, planning, and execution of a Project Management Office (PMO) that supports the National Cancer Institute’s Experimental Therapeutics program (NExT).
Senior Vice President/ Business Unit General Manager: Healthcare Solutions
August 3, 2009: The Stevenson Group has announced the placement of Anthony Hess, Ph.D., as Senior Vice President and Business Unit General Manager at SAIC Health Solutions Business Unit (HSBU). Hess most recently served as Chief Executive Officer at HealthCare IT, a biomedical IT software and services company. He also served as President and Chief Operating Officer at Capital Technology Information Services (CTIS), a health informatics firm, and held key executive positions at IBM, where he was responsible for leading business development and delivery efforts for the full suite of IBM healthcare products sold to federal, state, and local governments. Mr. Hess also played a key role within the Battelle Memorial Institute's government sector, where he led the strategic planning and organization of physical and computational facilities for the contract research business. At SAIC, Mr. Hess will be responsible for developing and managing SAIC's work for federal government and commercial health customers, including the Departments of Defense, Health and Human Services, and Veterans Affairs.
Vice President, Clinical Operations: Biotech Industry
June 15, 2009: The Stevenson Group has recruited Jennifer Hodge as Vice President of Clinical Operations at Quark Pharmaceuticals in Fremont, CA. Ms. Hodge brings to Quark more than 20 years of extensive drug development experience spanning discovery through commercialization gained in the US, Canada and UK. She joins Quark from Nile Therapeutics, where she served as Vice President of Development. In this role, she was responsible for identifying and implementing outsourced solutions to address all operational development requirements. Prior to Nile Therapeutics, Jennifer was a Director of Project Management for CV Therapeutics, Inc. where she was responsible for implementing initiatives by creating short and long-term development plans. Earlier in her career, Ms. Hodge served as Global Clinical Team Leader and Clinical Operations Manager for such companies as Quintiles, Otsuka, and Solvay. At Quark Pharmaceuticals, Ms. Hodge will be responsible for providing global leadership within the Clinical Operations organization as well as for setting direction, implementation, and monitoring of all clinical studies across Europe, US, India, and Israel.
Vice President, Medical Health Technology: Medical Technology
May 30, 2009: The Stevenson Group has recruited Allen B. Poirson, PhD as Vice President, Medical Health Technology at Sony Corporation of America. Mr. Poirson comes to Sony from Glaucoma Research Foundation, where as Director of Scientific Programs and Licensing he was responsible for overseeing licensing around new research initiatives through understanding the market and helping the foundation to prioritize research grants and pipeline. Prior to Glaucoma Research Foundation, Allen was the Vice President of Medical Systems for Science & Technology International. In this role, he directed R&D, clinical, regulatory, and commercialization efforts. In addition to his industry experience, Allen comes to Sony with a distinguished academic career in the scientific community. He has published extensively in scientific journals on topics including medical imaging, mathematics, biology, and computer science while holding research positions at Howard Hughes Medical Institute, NASA, and Stanford University. At Sony, Allen will be responsible for helping leverage existing capabilities and marry them to new business opportunities within the medical diagnostics and devices marketplace.
Director of IT/ Quality Control: Preclinical/ Clinical Services
May 1, 2009: The Stevenson Group has announced the placement of Eric J. Staib as Director of IT/Quality Control for Covance, Inc. Mr. Staib comes to Covance with a scientific quality and regulatory background and a solid industry experience. In his last role as a Director of Global Quality Improvement and Harmonization at Sanofi-Pasteur, Mr. Staib was actively assessing and aligning R&D quality systems for GMP, GLP, and GCP functions to ensure regulatory compliance (FDA/EMEA/Health Canada) and uniformity and harmonization across the global sites. He has also authored and implemented several R&D global quality directives including requirements for GCP, GLP, GCLP, Quality Management of Product Development and Testing, and an R&D Quality Manual. Prior to Sanofi-Pasteur, Eric worked as a Validation Specialist at CimQuest where he led and managed several global IT and laboratory quality and compliance consulting projects for their pharmaceutical and biotech clients. Mr. Staib is a Certified Quality Auditor and Six Sigma Champion. At Covance, Eric will be responsible for developing the strategy and executing all quality and validation activities for the company’s global applications as they are implemented in the Covance environment.
Executive Director, Medical Communications: Pharmaceutical Industry
April 9, 2009: The Stevenson Group has recruited Matthew Cahill as Executive Director, Medical Communications at Merck & Co., Inc. in Upper Gwynedd, Pennsylvania. Matt comes to Merck with nearly 30 years of experience in medical and healthcare publishing, having worked for such companies as McGraw-Hill, Springhouse Corporation (part of Reed Elsevier) and most recently Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. As Vice President of Nursing & Health Profession Journals at Lippincott, Williams and Wilkins, Matt grew the paid subscriber base for these journals to well over 1 million readers. At Springhouse Corporation, Matt began his career as Managing Editor in the company’s Book Division and rose to become its Senior Vice President by 1998. At Merck, Matt will be responsible for developing an integrated franchise publication strategy as well as establishing, maintaining, and fostering relationships with External Scientific and Editorial leaders.
Senior Director, Clinical Development, Inflammation: Biotech Industry
January 15, 2009: The Stevenson Group has announced the placement of Zafer Ozturk, MD who joins MedImmune, Inc. as Senior Director, Clinical Development – Inflammation. Dr. Ozturk comes to MedImmune from Hoffman-La Roche and brings over 19 years of experience in the Pharmaceutical industry gained at major pharmaceutical companies such as Sandoz and Merck. As a Medical Director of Immunology at Roche, Dr. Ozturk was responsible for the development of Phase IIIB/IV program for an osteoporosis drug and for leading the US medical team activities including clinical research operations, exploratory data analysis, publication plans, and medical education.
Director, Clinical Development, Inflammation: Biotech Industry
January 15, 2009: The Stevenson Group has recruited Warren Greth, MD to join MedImmune, Inc. as Director, Clinical Development – Inflammation. Dr. Greth comes to MedImmune from Hoffmann La-Roche, where as an Associate Clinical Director, he was responsible for designing protocols, medical monitoring, and interaction with experts regarding pediatric clinical development programs for juvenile arthritis. While working at Roche, he was also involved in internal clinical data review and provided scientific input for the design of two adult studies in rheumatoid arthritis. Prior to his role at Roche, Dr. Greth was an Associate Clinical Director at Centocor, where he was in charge of medical monitoring of a global trial for psoriatic arthritis.
Senior Medical Director, Rheumatology: Biotech Industry
January 15, 2009: The Stevenson Group has announced the placement of Dominique Ethgen, MD at MedImmune, Inc. Dr. Ethgen will join the Company as Senior Medical Director of Rheumatology. He is a seasoned senior medical leader with over 20 years of clinical research and drug development experience in musculoskeletal diseases, bone, and rheumatoid arthritis. Prior to joining MedImmune, Dr. Ethgen served as Senior Director, Clinical Development, Immune Mediated Diseases at GlaxoSmithKline. Before his tenure at GSK, Dr. Ethgen spent about nine years at Procter & Gamble Pharmaceuticals where he was involved in bone and mineral clinical research in the US and Europe and the implementation of disease management programs and outcome research studies in Osteoporosis. At MedImmune, Dr. Ethgen will lead clinical development efforts in the areas of Rheumatoid Arthritis, Lupus, and Scleroderma.
Medical Director, Vaccine Development: Biotech Industry
January 15, 2009: The Stevenson Group has announced the placement of Robert Gasser, MD who joins MedImmune, Inc. as Medical Director of Vaccine Development. Dr. Gasser comes to MedImmune from the Walter Reed Army Medical Center in Washington, DC where he most recently served as a Hospital Medicine Physician in the General Internal Medicine Service. At Walter Reed, he supervised direct care provided to hospitalized patients, taught residents and medical students, and conducted research in the infectious diseases arena. Prior to his most recent role, he served as a Deputy Director of Division of Communicable Diseases and Immunology, where he led a biomedical research division of 260 scientists and support staff developing vaccines against endemic tropical diseases.
Executive Medical Director, Nephrology/ Transplantation: Biotech Industry
November 30, 2008: The Stevenson Group has recruited Martin Polinsky, MD as Executive Medical Director, Nephrology/ Transplantation at Quark Pharmaceuticals. Dr. Polinsky, a seasoned Nephrologist with more than 30 years of experience working as a medical doctor and medical monitor for clinical trials, joins Quark from Wyeth Research. At Quark, Dr. Polinsky will oversee, screen, and evaluate study proposals as well as collaborate with the R&D department and other senior management in assessing requirements for emerging products.
Vice President, Software Engineering: Medical Technology
July 1, 2008: The Stevenson Group has announced the placement of Michael Meissner, PhD as Vice President, Software Engineering Omnyx, a digital pathology joint venture of GE Healthcare and the University of Pittsburgh Medical Center (UPMC). Dr. Meissner joins Omnyx from Vital Images, where he served as Vice President, Engineering, Senior Director, Engineering and Director, Enterprise Infrastructure, leading a team of 115 engineers and the development of two successful product releases of a client server based enterprise-wide advanced visualization system (ViTALConnect). Prior to Vital Images, Dr. Meissner was the Director of R&D at Viatronix, a radiology based imaging solution company with a flagship product in Virtual Colonoscopy. At GE Healthcare, Dr. Meissner will be responsible for leading all aspects of the software/program development and engineering as well as working with the senior management team to set the business and product vision and expectations for future software products.
Medical Director, Clinical Services: Preclinical/ Clinical Services
June 30, 2008: The Stevenson Group has announced the placement of Patricia A. Chandler, MD as Medical Director, Clinical Services - Northwest at Charles River Laboratories in Tacoma, WA. Dr. Chandler has six years of experience in industry, as a Medical Director and Principal Investigator on Phase I-II clinical studies, gained at Covance Clinical Research, Inc., PrimaCare Medical Centers, and nTouch Research. Her expertise includes conducting clinical trials in CNS, Depression, Neurology, Endocrine, Infectious Diseases, Hepatitis B and C, HIV, Diabetes, Hypertension, and Rheumatology. Prior to joining Charles River Laboratories, Dr. Chandler was a Medical Director at Covance’s 100-bed research unit in Dallas, TX (formerly Radiant Research), where she was involved in clinical research methodology including protocol review and study design from medical, safety, scientific, and feasibility viewpoints. At Charles River, Dr. Chandler will be responsible for overseeing the conduct of all studies to assure the medical safety and validity of every trial and to assure compliance with all company policies, SOPs, state and federal regulations.
Vice President, Customer Strategy and Senior Director, Market Strategy: Pharmaceutical Industry
May 26, 2008: The Stevenson Group has announced the placement of two key executives at Pfizer, Inc. Ms. Robyn Peters will serve as Vice President, Customer Strategy and Mr. John Paik will serve as Senior Director, Market Strategy at Pfizer’s newly created Customer Business Unit. Ms. Peters, who joins Pfizer from Boehringer-Ingelheim and possesses over 18 years of healthcare industry experience managing payer markets, will lead the Customer Strategy Group in development of effective business strategy as it relates to Managed Markets and their organized customers. Mr. Paik, who previously worked at Aetna as Head of Strategic Marketing for the National Businesses and Retiree Markets, will provide market insight and oversee the execution of action plans for the US market.
Vice President/ Global Medical Director, Respiratory: Pharmaceutical Industry
March 31, 2008: The Stevenson Group has announced the placement of Donald D. Banerji, MD as Vice President, Global Medical Director - Respiratory at Novartis Pharmaceuticals. Dr. Banerji joins Novartis with 19 years of experience in clinical research and development of pulmonary and allergy compounds. Most recently, Dr. Banerji was the Associate Vice President for Pulmonary Therapeutic Area at Sanofi-Aventis. Prior to joining Sanofi-Aventis, he served as a Director of Global Clinical Research and Global Clinical Project Leader, Corticosteroids at Rhone Poulenc Rorer Pharmaceuticals. Dr. Banerji has been recognized for his work and has written numerous articles on the topic of Allergy and Asthma.
Global Director, Scientific Affairs, Neuroscience: Pharmaceutical Industry
January 7, 2008: The Stevenson Group announced the placement of Marcelo Bigal, MD as Global Director, Scientific Affairs – Neuroscience at Merck. Dr. Bigal, an accomplished neurologist with expertise in mechanisms of migraine, joins Merck from the Montefiore Headache Center where he was the Director of Research, and the Albert Einstein College of Medicine where he served as an Assistant Professor of Neurology. Dr. Bigal has received numerous awards and published over 130 scientific articles. He currently serves as a Co-Director and Chairman of several prominent neurological societies and committees.
Senior Vice President/ Chief Strategic Marketing Officer: Consumer Electronics
November 15, 2007: The Stevenson Group has recruited Steven Cook as Senior Vice President, Chief Strategic Marketing Officer at Samsung Electronics. Cook joins Samsung with 26 years of global and local strategic brand, customer, and retail marketing experience. Most recently, Cook was Vice President of Worldwide Strategic Planning and Business Development at Coca-Cola. He also worked at Procter & Gamble, where he led the Brand, Sales and Distributor team for Cover Girl and Max Factor cosmetics and fragrances in Europe.
Vice President, Global Brand Medical Director, Respiratory: Pharmaceutical Industry
September 24, 2007: The Stevenson Group has recruited Benjamin Kramer, MD as Vice President, Global Brand Medical Director - Respiratory at Novartis. Dr. Kramer, an exceptionally seasoned medical professional with domestic and global experience, is a Board Certified Allergist and Immunologist with a concentration in the Respiratory area. Prior to joining Novartis, he worked for Pfizer where he received promotions from Medical Director to Senior Medical Director, Group Leader, and finally Vice President. Dr. Kramer has been recognized for an outstanding ability to build effective teams through coaching and mentoring.
Vice President, Late Stage Clinical Development Statistics: Pharmaceutical Industry
March 26, 2007: The Stevenson Group has recruited Jerald Schindler, PhD as Vice President, Late Stage Clinical Development Statistics at Merck, Inc. Dr. Schindler joins Merck from Cytel, Inc. where he served as President of the Pharmaceutical Research Division. Prior, he was Assistant Vice President and Chief Statistician at Wyeth. With over 20 years of pharmaceutical industry experience, Dr. Schindler has served on several Pharmaceutical Industry Advisory Boards in leadership positions, and is considered a thought leader in the area of Adaptive Trials.
Executive Medical Director, External Medical & Scientific Affairs, Neuropsychiatry: Pharmaceutical Industry
June 15, 2006: The Stevenson Group has placed Craig Karson, MD as Executive Medical Director, External Medical and Scientific Affairs - Neuropsychiatry at Merck, Inc. Dr. Karson previously held the Senior Director/ Clinical Research Director - Psychiatry position at Sanofi-Aventis. The Stevenson Group, located in Fort Lee, NJ and St. Prex Switzerland, are industry specialists in the healthcare and life sciences markets.
Executive Medical Director, External Medical and Scientific Affairs, Diabetes: Pharmaceutical Industry
June 1, 2006: The Stevenson Group has placed Sethu Reddy, MD as Executive Medical Director, External Medical and Scientific Affairs – Diabetes, US Human Health at Merck. Dr. Reddy previously held the Chair of the Department of Endocrinology, Diabetes and Metabolism at the Cleveland Clinic Foundation. The Stevenson Group, located in Fort Lee, NJ and St. Prex Switzerland, are industry specialists in the healthcare and life sciences markets.
Senior Cardiovascular/ Metabolics Medical Expert: Pharmaceutical Industry
2006: The Stevenson Group, a Global Retained Executive Search Firm, has placed Giovanni Sperti, MD as Senior CVM Medical Expert at Novartis. Previously Dr. Sperti was with Bristol-Myers Squibb Pharmaceutical where he served as the Executive Medical Director, Cardiovascular and Metabolics Europe. Other positions that Dr. Sperti held within Bristol- Myers Squibb over his seven year career include Executive Medical Director, North-West Europe and Cardiovascular Therapeutic Area Director in the UK and Italy respectively. The Stevenson Group, located in Fort Lee, NJ and St. Prex, Switzerland, are industry specialists in the healthcare and life sciences markets.
General Manager/ Divisional Vice President, Reno-Preclinical Services: Preclinical/ Clinical Services
2006: The Stevenson Group has placed Stephen Durham, PhD as General Manager and Divisional Vice President, Reno-Preclinical Services at Charles River Laboratories. Previously Dr. Durham was with Bristol-Myers Squibb Pharmaceutical Research Institute where he served as the Executive Director, Drug Safety Evaluations for four years. Other positions that Dr. Durham held within Bristol-Myers Squibb include Executive Director, Preclinical Candidate Optimization and Executive Director, Department of Lead Safety Assessment. The Stevenson Group, located in Fort Lee, NJ and St. Prex, Switzerland, are industry specialists in the healthcare and life sciences markets.
Vice President/ Global Head, Cardiovascular: Pharmaceutical Industry
2006: The Stevenson Group has recruited The Stevenson Group Mathieu Ghadanfar, MD as Vice President, Global Head - Cardiovascular at Novartis. In his sixteen year career at Pfizer, Dr. Ghadanfar held various key positions with the most recent one being the Senior Director, Worldwide Medical Team Leader. The Stevenson Group, located in Fort Lee, NJ and St. Prex, Switzerland, are industry specialists in the healthcare and life sciences markets.